Evidence map›Paper›PMID 39602812›Full record

Trial reportJMIR mental health2024

Avatar Intervention in Virtual Reality for Cannabis Use Disorder in Individuals With Severe Mental Disorders: Results From a 1-Year, Single-Arm Clinical Trial.

Sabrina Giguere, Mélissa Beaudoin, Laura Dellazizzo, Kingsada Phraxayavong, Stéphane Potvin, Alexandre Dumais

Abstract readClinical Trial
In one paragraph

Trial report in JMIR mental health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Quality of life measures in treatment for active substance misuse: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sabrina GiguereDepartment of Psychiatry and Addictology, University of Montreal, 2900 boulevard Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada.ORCID 0000-0003-1254-7217
Mélissa BeaudoinDepartment of Psychiatry and Addictology, University of Montreal, 2900 boulevard Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada.ORCID 0000-0002-0169-8055
Laura DellazizzoDepartment of Psychiatry and Addictology, University of Montreal, 2900 boulevard Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada.ORCID 0000-0001-8262-130X
Kingsada PhraxayavongResearch Center of the University Institute in Mental Health of Montreal, Montreal, QC, Canada.ORCID 0000-0003-3113-9104
Stéphane PotvinDepartment of Psychiatry and Addictology, University of Montreal, 2900 boulevard Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada.ORCID 0000-0003-1624-378X
Alexandre DumaisDepartment of Psychiatry and Addictology, University of Montreal, 2900 boulevard Édouard-Montpetit, Montreal, QC, H3T 1J4, Canada.ORCID 0000-0002-4480-0064

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The dual diagnosis of cannabis use disorder (CUD) and severe mental disorder (SMD) results in clinically complex individuals. Cannabis use is known to have negative consequences on psychiatric symptoms, medication compliance, and disease prognosis. Moreover, the effectiveness of currently available psychotherapeutic treatments is limited in this population. In this context, our research team developed avatar intervention, an approach using virtual reality as a therapeutic tool to treat CUD in individuals with SMD. Objective: This pilot clinical trial aimed to evaluate, until the 1-year follow-up, the efficacy of avatar intervention for CUD among 32 participants with a dual diagnosis of SMD and CUD. Methods: Over the course of the 8 intervention sessions, participants were given the opportunity to enter a dialogue in virtual reality with an avatar representing a person with a significant role in their consumption, who was animated in real time by a therapist. The primary outcomes were the quantity of cannabis consumed and the frequency of use. Secondary outcomes included severity of problematic cannabis use, motivation for change, protective strategies for cannabis use, consequences of cannabis use, psychiatric symptoms, and quality of life. Changes in reported outcomes during the assessment periods before the intervention; postintervention; and 3, 6, and 12 months after the end of the intervention were assessed using a linear mixed-effects model. Results: Significant reductions were observed in the quantity of cannabis consumed, and these were maintained until the 12-month follow-up visit (d=0.804; P<.001; confirmed by urine quantification). Frequency of cannabis use showed a small significant reduction at the 3-month follow-up (d=0.384; P=.03). Moreover, improvements were observed in the severity of CUD, cannabis-related negative consequences, the motivation to change cannabis use, and the strategies used to mitigate harms related to cannabis use. Finally, moderate benefits were observed for quality of life and psychiatric symptoms. Conclusions: Overall, this unique intervention shows promising results that seem to be maintained up to 12 months after the end of the intervention. With the aim of overcoming the methodological limitations of a pilot study, a single-blind randomized controlled trial is currently underway to compare the avatar intervention for CUD with a conventional addiction intervention.

Indexed as

Marijuana AbuseMental DisordersVirtual RealityAdultAvatarDiagnosis, Dual (Psychiatry)FemaleFollow-Up StudiesHumansMaleMiddle AgedPilot Projectsaddiction interventionavatarcannabis usecannabis use disorderdigital mental healthrelational therapyvirtual realityvirtual reality therapy

Identifiers

PMID39602812
PMCPMC11612600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.